These findings indicate a potential link between COX-2 and obesity and MASLD pathogenesis (10, 11) and suggest that inhibition of COX-2 may be an effective strategy in managing MASLD. Here, PTGS2 is linked to metabolic dysfunction-associated steatotic liver disease.